<code id='B523495A5D'></code><style id='B523495A5D'></style>
    • <acronym id='B523495A5D'></acronym>
      <center id='B523495A5D'><center id='B523495A5D'><tfoot id='B523495A5D'></tfoot></center><abbr id='B523495A5D'><dir id='B523495A5D'><tfoot id='B523495A5D'></tfoot><noframes id='B523495A5D'>

    • <optgroup id='B523495A5D'><strike id='B523495A5D'><sup id='B523495A5D'></sup></strike><code id='B523495A5D'></code></optgroup>
        1. <b id='B523495A5D'><label id='B523495A5D'><select id='B523495A5D'><dt id='B523495A5D'><span id='B523495A5D'></span></dt></select></label></b><u id='B523495A5D'></u>
          <i id='B523495A5D'><strike id='B523495A5D'><tt id='B523495A5D'><pre id='B523495A5D'></pre></tt></strike></i>

          Wikipedia

          Wikipedia

          author:fashion    Page View:87565
          A scientist working at SQZ Biotechnologies in Watertown's Arsenal Yards. -- biotech coverage from STAT
          A scientist working at SQZ Biotechnologies in Watertown, Mass. David L Ryan/Globe Staff

          Next stop: Beacon Hill.

          Governor Maura Healey’s long-awaited plan to double down on state funding for the biotech and medical technology sector came into focus Thursday with the announcement she’ll seek $1 billion over the next decade to reauthorize the state’s 16-year-old life sciences initiative.

          advertisement

          But lawmakers so far are noncommittal on funding the plan. The proposal — dubbed “Life Sciences 3.0″ — is part of a larger economic development bill the Healey administration is expected to file soon. Several expressed support for an industry in which Massachusetts is a leader, but also noted the spending request comes at a time of competing priorities.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Psychedelics group wrestles with new pharma identity
          Psychedelics group wrestles with new pharma identity

          OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

          read more
          Clinical trials giant ICON acquires HumanFirst
          Clinical trials giant ICON acquires HumanFirst

          AdobeAspharmacompanieswrestlewithhowandwhentousewearablesandotherdigitaltechnologiestomeasurehowthei

          read more
          Drug repurposing or repositioning? The language matters
          Drug repurposing or repositioning? The language matters

          AdobeFindinganewmedicineisnevereasy.Butdevelopingtreatmentsforpatientswithrarediseases—conditionstha

          read more

          Surge in Apellis stock fueled by confidence in safety of its eye drug

          MollyFerguson/STATSharesofApellisPharmaceuticalsarerebounding,drivenbyagrowingbeliefamongsomeinvesto